Compare Cassava Sciences Inc (FLNA) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Harley-Davidson Inc — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Harley-Davidson Inc trades at $26.76 (market cap $2.73B). The key difference: Harley-Davidson Inc is far larger — about 51.4× Cassava Sciences Inc's market cap, and Harley-Davidson Inc pays a 2.83% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | HOG | |
|---|---|---|
Market Cap | $53.14M | $2.73B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $31.03 |
52-Week Low | $1.09 | $17.19 |
Enterprise Value | -$33.43M | $3.13B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Harley-Davidson (HOG) trades at $25.11, down 1.1% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. Recent earnings have been volatile, with Q1 2026 missing estimates despite revenue growth. The company is executing a turnaround strategy including U.S. production reshoring and cost cuts, reflected in improving cash flow trends but declining revenue and margins since 2022.
The outlook hinges on margin recovery from operational reset initiatives, but risks include competitive pressures and execution challenges. Analysts are cautious with 65.7% hold ratings, though some see value at current valuations. The stock faces near-term pressure with consensus price target below current levels, requiring successful turnaround execution for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
